The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
|Articles|January 1, 2002
- Pharmaceutical Technology-01-02-2002
- Volume 26
- Issue 1
Manufacturers Face Shifting Priorities in the New Year
Author(s)Jill Wechsler
Pharmaceutical companies will face a number of issues and challenges this year that will affect their resources, operations, and the markets they serve.
Advertisement
Articles in this issue
almost 25 years ago
What Does Pharmacy Automation Mean for Packaging?almost 25 years ago
Novel Acrylate Adhesives for Transdermal Drug Deliveryalmost 25 years ago
Optimal Tablet Press Operation: Machine versus Granulationalmost 25 years ago
Investigation of Out-of-Specification Resultsalmost 25 years ago
Reaping the Benefits of E-Procurementalmost 25 years ago
Outsourcing OutlookAdvertisement
Related to this article
The FDA approves asundexian, the first factor XIa inhibitor, cutting stroke risk 26% and setting a regulatory benchmark for factor XI drug developers.
No operator touches a CAR-T batch before demonstrating proficiency. Generative AI users should meet the same standard, and a higher one, because an AI error does not stay inside one batch.
The FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer, extending the IV-to-subcutaneous shift in biologics formulation.
Regulators will test pharma companies against their own internal AI policies. Jaenisch, Muraru, and Pandey explain how to build defensible, inspection-ready AI practices.
FDA approved pimicotinib for TGCT based on a 56% response rate; its Project Orbis review signals tighter global launch planning for manufacturers.
From AI validation to microstructure imaging, AAPS PharmSci 360 speakers pushed toward faster drug development backed by stronger evidence. Here are PharmTech's biggest takeaways.
Panelists on the PharmTech AI Pulse Check weigh a December AI playbook, EMA/MHRA moves, PCCP accountability gaps, and MCP-ready regulatory guidance.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
$1.15B AI-Guided Macrocycle Discovery Lands at argenx
3
Pimicotinib TGCT Approval Shows How Assessment Aid Supports Review
4
Our Biggest Takeaways From AAPS PharmSci 360
5